The DIAAMOND-Ava NEXT Trial : Avatrombopag iN Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy – a Bayesian Optimal Phase II study

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAplastic Anaemia

Trial Overview Read MoreRead more

In this phase II trial, patients with severe aplastic anaemia who have been treated with, but not responded to immunosuppressive therapy (IST), will receive a new drug (avatrombopag) as a potential treatment for their condition.
 

This trial is treating patients with aplastic anaemia.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Avatrombopag iN Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy – a Bayesian Optimal Phase II study

Other Non-Commercial Sponsor

Monash University

Summary

Eligible patients will receive oral avatrombopag at a maximum dose of 60mg per day, for up to 180 days. Dose will be adjusted every 2 weeks guided by reticulocyte count, platelet count/platelet transfusion and neutrophil count.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Clayton
Ms Anita Cummins
anita.cummins@monashhealth.org
03 9594 4044

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next